Pharmacy Times

Pharmacy Times is a monthly magazine aimed at pharmacists, published by Intellisphere, LLC. It offers valuable clinical insights that pharmacists can apply in their daily work. Every issue includes articles and features on various topics such as pharmacy trends, medication mistakes, drug interactions, educating patients, pharmacy technology, managing diseases, counseling patients, updates on products, pharmacy regulations, and specialty pharmacy. The magazine is located in Plainsboro, New Jersey.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#123917

United States

#35892

Health/Health

#837

Traffic sources

Monthly visitors

Articles

Study Links PAK5 to Poor Outcomes and Drug Resistance in HER2-Positive Breast Cancer

1 day ago | pharmacytimes.com | Alexandra Gerlach

Researchers have identified p21-activated kinase 5 (PAK5) as a potential therapeutic target for overcoming trastuzumab emtansine (T-DM1, Kadcyla; Genentech) resistance in human epidermal growth factor receptor-positive (HER2+) breast cancer (BC), according to study findings published in Cell Death & Disease.1In 2023, approximately 290,000 women were diagnosed with HER2+ BC, which represents 20% of all BC diagnoses.
Thrombosis May Increase Risk of Cardiovascular Disease, Secondary Cancers in Myeloproliferative Neoplasms

2 days ago | pharmacytimes.com | Alexandra Gerlach

Researchers have found associations between arterial and venous thrombosis and mortality, disease progression, cardiac events, and second cancers (SC) in myeloproliferative neoplasms (MPNs). The data, published in Blood Cancer Journal, suggest that common inflammatory pathways driving disease progression in MPNs could influence cardiovascular disease (CVD) and cancer incidence.1MPNs are clonal illnesses of the bone marrow and blood cells that are distinguished by aberrant hematopoietic growth.
Amid the Ongoing Measles Outbreak, Cases of Whooping Cough Are on the Rise

2 days ago | pharmacytimes.com | Alexandra Gerlach

Cases of pertussis, also known as whooping cough, are on the rise alongside the ongoing measles outbreak as vaccination rates decline in children.
Trastuzumab Deruxtecan Plus Pertuzumab Improves Progression-Free Survival in Patients With HER2+ Metastatic Breast Cancer

3 days ago | pharmacytimes.com | Alexandra Gerlach

Trastuzumab deruxtecan (T-DXd, Enhertu; AstraZeneca) in combination with pertuzumab (Perjeta; Genentech) demonstrated clinically meaningful improvement in progression-free survival (PFS) compared with a taxane, trastuzumab, and pertuzumab (THP) as a first-line treatment for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC).
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders

6 days ago | pharmacytimes.com | Alexandra Gerlach

As of April 18, 2025, the CDC has reported a total of 800 measles cases across the nation. Although the outbreak remains most concentrated in Texas, cases have now been confirmed in at least 12 states, as well as across the borders into Mexico and Canada. This represents a 12% increase from the prior week. The outbreak has led to 2 confirmed pediatric deaths and 1 case that is still under investigation.
Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients

6 days ago | pharmacytimes.com | Alexandra Gerlach

Real-world outcomes of momelotinib (Ojjaara; GSK) in patients with myelofibrosis (MF) support the agent’s efficacy and capabilities in improving symptoms, reducing spleen size, increasing hemoglobin (Hb) levels, and reducing transfusion dependency in both Janus kinase (JAK) inhibitor-naïve and JAK inhibitor-exposed patients, which has been demonstrated in several clinical trials.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria

6 days ago | pharmacytimes.com | Luke Halpern

NewsArticleApril 18, 2025Author(s): Dupilumab (Dupixent) is now FDA-approved for CSU in patients 12+ unresponsive to H1 antihistamines. This approval marks the first new CSU treatment in over a decade, offering new management options. Kenneth Mendez emphasizes the significant impact of this approval on patients' quality of life and disease control.
Real-World Data Show Improved Survival With Sacituzumab Govitecan as First-Line ADC in HER2-Low Breast Cancer

6 days ago | pharmacytimes.com | Alexandra Gerlach

Patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC) experience longer time to treatment failure (TTF) and real-world overall survival (rwOS) when treated with sacituzumab govitecan (SG, Trodelvy; Gilead Sciences) as the first antibody-drug conjugate (ADC) compared with trastuzumab deruxtecan (T-DXd, Enhertu; Trodelvy, AstraZeneca) administered second.
Lepodisiran Reduces Lipoprotein(a) By Nearly 94% in Adults With Elevated Levels of Lp(a)

6 days ago | pharmacytimes.com | Luke Halpern

Lepodisiran (Eli Lilly), an investigational small interfering RNA (siRNA) therapy designed to reduce the production of lipoprotein(a) [Lp(a)], meaningfully reduced Lp(a) levels by an average of 93.9% over a 60-to-180-day period in adults with high Lp(a) levels following treatment at the highest tested dose of 400 mg, according to results from the phase 2 ALPACA (NCT05565742) trial that were presented at the American College of Cardiology 2025 Scientific Sessions.1-3 The ALPACA study, a...
April 2025 Pharmacy Policy Updates

6 days ago | pharmacytimes.com | Luke Halpern |Alexandra Gerlach

Executive Order Advances Price Transparency EffortsAs part of the "Make America Healthy Again" movement, President Donald J. Trump signed an executive order (EO) to enforce stricter price transparency standards in the health care industry to help lower costs for Americans.